ME 1036

Drug Profile

ME 1036

Alternative Names: CP 5609; ME-1036

Latest Information Update: 09 Feb 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Meiji Seika Kaisha
  • Class Carbapenems
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections; Haemophilus infections; Methicillin-resistant Staphylococcus aureus infections; Pneumococcal infections; Skin and soft tissue infections

Most Recent Events

  • 09 Feb 2009 Discontinued - Phase-I for Bacterial infections in North America (Parenteral)
  • 09 Feb 2009 Discontinued - Preclinical for Haemophilus infections in Japan (Parenteral)
  • 09 Feb 2009 Discontinued - Preclinical for Meticillin-resistant Staphylococcus aureus infections in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top